Direct to clinic, in the markets where access exists.

Optimi supplies finished-dose psilocybin and MDMA capsules through regulated medical-access pathways. Products reach patients via authorized prescribers under the frameworks listed below.

This page covers Optimi's active supply pathways. For the broader global regulatory landscape, see knowledge · regulatory →